Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials.

ABSTRACT:

Introduction

Patients with atopic dermatitis (AD) have high disease burden negatively affecting quality of life.

Aim

To assess the efficacy and safety of dupilumab in patients with moderate-to-severe AD.

Material and methods

A systematic literature search was performed using the main-stream databases of PubMed, Web of Science, and Embase. Standard mean difference (SMD) or risk ratios (RR) with 95% confidence interval (95% CI) were calculated using a fixed-effects or random-effects model.

Results

A total of 11 studies with 4094 patients met the inclusion criteria and were included in this meta-analysis. Pooled estimate showed that dupilumab significantly improved the mean change in the Eczema Area and Severity Index (EASI) score (SMD = -10.90, 95% CI: -12.13, -9

SUBMITTER: Wu S 

PROVIDER: S-EPMC9326918 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature